Efficacy of Omalizumab Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)

EDİGER D., ERBAY M., Seker Ü.

ASTIM ALLERJI IMMUNOLOJI, vol.20, no.1, pp.25-30, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.21911/aai.644
  • Journal Name: ASTIM ALLERJI IMMUNOLOJI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.25-30
  • Keywords: Asthma-COPD overlap, exacerbation, hospitalization, omalizumab, pulmonary function
  • Bursa Uludag University Affiliated: Yes

Abstract

Objective: Although the precise definition of asthma-chronic obstructive pulmonary disease overlap (ACO) is still controversial, patients sharing common features of both diseases are frequently seen in clinical practice. Current literature suggests that patients with ACO have higher risk of morbidity and mortality than those with asthma or chronic obstructive pulmonary disease (COPD) alone. Omalizumab, a monoclonal anti-IgE monoclonal antibody, has proven to be effective in moderate-to-severe allergic asthma, but data on the efficacy of omalizumab in patients with ACO are limited. To determine the efficacy of omalizumab in patients with ACO.